PT-112 is the first pyrophosphate-platinum conjugate in oncology clinical development, with a multimodal mechanism of action shown to promote immunogenic cancer cell death (ICD), including increases in relevant immune cell populations (i.e. dendritic cells and cytotoxic / helper T cells) in pre-clinical model systems. Added value of the study.

2020年2月11日 · PT-112 is a novel platinum-pyrophosphate conjugate under clinical development for cancer therapy. PT-112 mediates cytostatic and cytotoxic effects against a variety of human and mouse cancer cell lines in vitro. The cytotoxic response to PT-112 is associated with the emission of danger signals underpinning the initiation of anticancer immunity ...

2023年2月21日 · Preclinical studies have shown the robust induction of immunogenic cell death by PT-112, leading to an anti-cancer adaptive immune response. Biodistribution experiments in mice showed PT-112’s partial bone affinity.

PT-112 is a novel pyrophosphate-platinum conjugate, with clinical activity reported in advanced pretreated solid tumors. While PT-112 has been shown to induce robust immunogenic cell death (ICD) in vivo but only minimally bind DNA, the molecular mechanism underlying PT-112 target disruption in cancer cells is still under elucidation.

2023年5月31日 · PT-112, a novel inducer of immunogenic cell death, has demonstrated safety and efficacy in phase I trials. We present results of an unplanned interim analysis of a phase 2, NIH IRB-approved clinical trial to evaluate the clinical activity, tolerability, and correlative immunology of PT-112 in TETs (NCT05104736).

PT-112 is a novel platinum-pyrophosphate conjugate under clinical development for cancer therapy. PT-112 mediates cytostatic and cytotoxic effects against a variety of human and mouse cancer cell lines in vitro. The cytotoxic response to PT-112 is associated with the emission of danger signals underpinning the initiation of anticancer immunity ...

2023年12月1日 · PT-112 is a novel immunogenic small molecule under Phase 2 development in metastatic castration-resistant prostate cancer and thoracic malignancies. PT-112 has been shown to release damage-associated molecular patterns, essential immune signaling components of immunogenic cell death (ICD), and to elicit anticancer immune responses.

PT-112 inhibits ribosomal biogenesis (RiBi) and selectively kills cancer cells. PT-112’s best-in-class ICD effects stimulate dendritic cells to recruit and activate T-cells to the tumor microenvironment (TME), creating the potential for effective and durable responses.

PT-112 induces a marked mitochondrial reactive oxygen species (ROS) accumulation in the most sensitive, glycolytic cells, together with mitochondria hyperpolarization, and induces the initiation of autophagy in all cell lines tested, although p62 degradation was not observed.

Imifoplatin (PT-112) 是一种铂类活性分子，属于磷铂家族。 Imifoplatin 可诱导细胞凋亡 ( Apoptosis )，具有抗肿瘤活性。 MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务